Lates News

date
13/08/2025
The weight loss drug of Eli Lilly and Company performed disappointingly in a key trial, after which the company's CEO, David Ricks, and other insiders bought a total of nearly $3 million worth of stock in subsequent stock sales. Eli Lilly's CEO, David Ricks, purchased $1 million worth of the company's stock on Tuesday. Following disappointing trial data for Eli Lilly's weight loss drug and a subsequent drop in stock price, several executives and board members of Eli Lilly saw an opportunity to buy. According to documents submitted to the Securities and Exchange Commission, five insiders at Eli Lilly collectively purchased $2.9 million worth of stock in the past few days. These insiders include Eli Lilly's CEO, David Ricks, who purchased slightly over $1 million worth of stock on Tuesday.